Stock Research for INFI


Featured Broker: Ally Invest

Get the due diligence for another stock.


INFI Stock Chart & Research Data

The INFI chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the INFI chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


INFI Due diligence Resources & Stock Charts

The INFI stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View INFI Detailed Price Forecast - CNN Money CNN View INFI Detailed Summary - Google Finance
Yahoo View INFI Detailed Summary - Yahoo! Finance Zacks View INFI Stock Research & Analysis -

Stock Analysis

TradeIdeas View INFI Trends & Analysis - Trade-Ideas Barrons View INFI Major Holders - Barrons
NASDAQ View INFI Call Transcripts - NASDAQ Seeking View INFI Breaking News & Analysis - Seeking Alpha
Spotlight View INFI Annual Report - OTC Report View INFI OTC Short Report -
TradeKing View INFI Fundamentals - TradeKing Charts View INFI SEC Filings - Bar Chart
WSJ View Historical Prices for INFI - The WSJ Morningstar View Performance/Total Return for INFI - Morningstar
MarketWatch View the Analyst Estimates for INFI - MarketWatch CNBC View the Earnings History for INFI - CNBC
StockMarketWatch View the INFI Earnings - StockMarketWatch MacroAxis View INFI Buy or Sell Recommendations - MacroAxis
Bullish View the INFI Bullish Patterns - American Bulls Short Pains View INFI Short Pain Metrics -

Social Media Mentions

StockTwits View INFI Stock Mentions - StockTwits PennyStocks View INFI Stock Mentions - PennyStockTweets
Twitter View INFI Stock Mentions - Twitter Invest Hub View INFI Investment Forum News - Investor Hub
Yahoo View INFI Stock Mentions - Yahoo! Message Board Seeking Alpha View INFI Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for INFI - Insider Cow View Insider Transactions for INFI - Insider Cow
CNBC View INFI Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for INFI - OTC Markets
Yahoo View Insider Transactions for INFI - Yahoo! Finance NASDAQ View Institutional Holdings for INFI - NASDAQ

Stock Charts

FinViz View INFI Stock Insight & Charts - StockCharts View INFI Investment Charts -
BarChart View INFI Stock Overview & Charts - BarChart Trading View View INFI User Generated Charts - Trading View

Latest Financial News for INFI

Free Technical Research on Insmed and Three More Biotech Equities
Posted on Friday July 13, 2018

On Thursday, July 12, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. All sectors ended Wednesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, assessed the following Biotechnology equities this morning: Infinity Pharmaceuticals Inc. (NASDAQ: INFI), Innoviva Inc. (NASDAQ: INVA), Inovio Pharmaceuticals Inc. (NASDAQ: INO), and Insmed Inc. (NASDAQ: INSM).

Infinity and Arcus Ink Deal for Two Triple Combo Studies
Posted on Wednesday June 27, 2018

: Infinity Pharmaceuticals, Inc. (INFI) and Arcus Biosciences, Inc. (RCUS) sign a deal to evaluate two triple combination therapies in selected tumor types.

Arcus Biosciences and Infinity Pharmaceuticals Announce Clinical Collaboration to Evaluate Lead Programs in Triple-Combination Studies
Posted on Tuesday June 26, 2018

HAYWARD, Calif. and CAMBRIDGE, Mass., June 26, 2018 /PRNewswire/ -- Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, and Infinity Pharmaceuticals, Inc. (INFI), a clinical-stage biopharmaceutical company developing IPI-549, a first-in-class immuno-oncology product candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma), today announced that they have entered into a clinical collaboration to evaluate two triple combination therapies in selected tumor types which typically show minimal response to checkpoint inhibition monotherapy. The collaboration will evaluate IPI-549 in combination with AB928, Arcus's dual adenosine receptor antagonist, and AB122, Arcus's anti-PD-1 antibody, as well as IPI-549 in combination with AB928 and chemotherapy in patients with triple negative breast cancer (TNBC) or ovarian cancer in four separate cohorts.

Is the Options Market Predicting a Spike in Infinity (INFI) Stock?
Posted on Monday June 25, 2018

Investors in Infinity (INFI) need to pay close attention to the stock based on moves in the options market lately.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.